Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myeloid leukemia: current treatment options.

J M Goldman1, B J Druker

  • 1Imperial College School of Medicine, London, United Kingdom. jgoldman@ic.ac.uk

Blood
|September 25, 2001
PubMed
Summary

Choosing the best initial treatment for chronic myeloid leukemia (CML) is complex. While stem cell transplants offer eradication, new tyrosine kinase inhibitors show promise for CML management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knight Scholars Program: A Tiered Three-Year Mentored Training Program for Urban and Rural High School High School Students Increases Interest and Self-Efficacy in Interprofessional Cancer Research.

Journal of STEM outreach·2023
Same author

Recurrent cyclin D2 mutations in myeloid neoplasms.

Leukemia·2017
Same author

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.

Leukemia·2016
Same author

Age-related mutations and chronic myelomonocytic leukemia.

Leukemia·2015
Same author

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Leukemia·2015
Same author

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.

Oncogene·2014

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Allogeneic stem cell transplantation offers leukemia eradication in chronic myeloid leukemia (CML) but has limited eligibility and significant risks.
  • Interferon-alpha (IFN-alpha) improves survival over hydroxyurea for most CML patients but causes substantial toxicity.
  • Newly approved tyrosine kinase inhibitors, like STI571, demonstrate high rates of hematologic and cytogenetic response in CML.

Purpose of the Study:

  • To review prognostic factors for survival in chronic phase CML patients undergoing non-transplantation therapy and allografting.
  • To discuss two primary management strategies for newly diagnosed chronic phase CML.
  • To evaluate the current role of allogeneic stem cell transplantation and emerging therapies like STI571.

Main Methods:

  • Review of existing literature on prognostic factors for CML survival.
  • Comparison of outcomes for different treatment modalities including stem cell transplantation, IFN-alpha, and STI571.
  • Analysis of survival predictors in chronic phase CML.

Main Results:

  • Allogeneic stem cell transplantation can eradicate CML, with graft-versus-leukemia effect being a key factor.
  • Interferon-alpha (IFN-alpha) provides a survival benefit compared to hydroxyurea but is limited by toxicity.
  • STI571 achieves high remission rates and cytogenetic responses, though long-term survival data versus IFN-alpha is pending.

Conclusions:

  • Allogeneic stem cell transplantation remains a viable option for select newly diagnosed chronic phase CML patients.
  • Further research on STI571, alone or in combination, is crucial and may reshape future CML treatment paradigms.
  • The optimal initial therapy for chronic phase CML requires careful consideration of patient eligibility, treatment risks, and emerging therapeutic options.

Related Experiment Videos